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Abstract
Objectives: Natural products have played a significant role in drug discovery and development. Inflammatory
mediators such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) have been suggested to
connect with various inflammatory diseases. In this study, we explored the anti-inflammatory potential of aciculatin
(8-((2R,4S,5S,6R)-tetrahydro-4,5-dihydroxy-6-methyl-2H-pyran-2-yl)-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4H-
chromen-4-one), one of main components of Chrysopogon aciculatis, by examining its effects on the expression
and activity of iNOS and COX-2 in lipopolysaccharide (LPS)-activated macrophages.
Methods: We used nitrate and prostaglandin E2 (PGE2) assays to examine inhibitory effect of aciculatin on nitric
oxide (NO) and PGE2 levels in LPS-activated mouse RAW264.7 macrophages and further investigated the
mechanisms of aciculatin suppressed LPS-mediated iNOS/COX-2 expression by western blot, RT-PCR, reporter gene
assay and confocal microscope analysis.
Results: Aciculatin remarkably decreased the LPS (1 μg/mL)-induced mRNA and protein expression of iNOS and COX-2
as well as their downstream products, NO and PGE2 respectively, in a concentration-dependent manner (1-10 μM). Such
inhibition was found, via immunoblot analyses, reporter gene assays, and confocal microscope observations that
aciculatin not only acts through significant suppression of LPS-induced NF-B activation, an effect highly correlated
with its inhibitory effect on LPS-induced IB kinase (IKK) activation, IBd e g r a d a t i o n ,N F - B phosphorylation, nuclear
translocation and binding of NF-Bt ot h eB motif of the iNOS and COX-2 promoters, but also suppressed
phosphorylation of JNK/p38 mitogen-activated protein kinases (MAPKs).
Conclusion: Our results demonstrated that aciculatin exerts potent anti-inflammatory activity through its dual
inhibitory effects on iNOS and COX-2 by regulating NF-B and JNK/p38 MAPK pathways.
Introduction
Natural products have proven to be a valuable source for
new therapeutic agents. In a search for anti-inflammatory
products, aciculatin (8-((2R,4S,5S,6R)-tetrahydro-4,5-dihy-
droxy-6-methyl-2H-pyran-2-yl)-5-hydroxy-2-(4-hydroxy-
phenyl)-7-methoxy-4H-chromen-4-one), was selected.
Aciculatin, isolated from whole plants of Chrysopogon aci-
culatis, has been used to treat fever and common cold as a
traditional Chinese medicine for centuries. Previous study
suggested that aciculatin exhibits cytotoxic effect through
DNA binding capacity against transformed human KB cell
line [1]. However, the molecular details and the anti-
inflammatory effect of aciculatin are still unclear.
Through up-regulation of inducible genes, macrophage
can secret numbers of inflammatory mediators that contri-
bute to inflammatory responses, including endotoxin-
mediated septic shock [2], rheumatoid arthritis [3,4],
asthma [5] and other inflammatory vascular disease [6].
Lipopolysaccharide (LPS), a component of the cell wall of
gram-negative bacteria, is known to activate a number of
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inflammatory enzymes, induc i b l en i t r i co x i d es y n t h a s e
(iNOS) and cyclooxygenase-2 (COX-2), which can be
induced by LPS or cytokines, are found to work in concert
in a number of similar pathophysiological activities and
inflammatory disease [8,9]. Under basal condition, the pro-
ducts of iNOS and COX-2, including nitric oxide (NO)
and prostaglandins (PGs), are involved in modulation of
cellular functions and homeostasis. They are highly regu-
lated by biosynthetic pathways that are responsible for
pulsed release of nanomolar concentrations of both med-
iators [10,11]. However, during inflammation, NO and
PGs are released simultaneously in large amounts up to
micromolar concentration [12]. Previous study has shown
that NO directly increases COXs activity and leads to a
remarkable 7-fold increase in PGE2 formation [13]; further
studies suggest that there is a considerable cross talk
between NO and PGs biosynthetic pathways [13,14].
Therefore, a compound with the dual inhibitory effect on
iNOS and COX-2 expression would hold tremendous
potential in advancing the treatment of inflammatory or
chronic immune disorders.
Proinflammatory mediators bind to specific receptors
cause transcriptional modulation on many genes involved
in the further inflammation process [15]. Targeting the
intracellular pathways activated between the receptors
and gene expression is an attractive concept to develop
new anti-inflamatory therapeutic agent, since different
proinflammatory mediators can share common intracel-
lular pathways [16]. A binding site for the universal tran-
scription factor NF-B has been identified in the
promoter regions of both the iNOS [17] and COX-2 [18]
genes. Inflammatory mediators such as LPS [19], cyto-
kines [20] or mitogen-activated protein kinase (MAPK)
members, such as p38 and c-Jun N-terminal kinase (JNK)
[21] stimulate the pathways by activating the inhibitor B
(IB) kinase (IKK) that phosphorylates IB and leads to
its degradation; the free NF-B could then be translo-
cated to the nucleus and induces the transcriptions of
iNOS [22] and COX-2 [23]. This pathway has been
known to modulate a wide variety of inflammatory sig-
naling pathways via the up-regulation of iNOS and COX-
2. Hence, it has become an attractive therapeutic target
for anti-inflammatory drug developments.
The present study examines the inhibitory effect of
aciculatin on the expression of iNOS, COX-2 and eluci-
dates the anti-inflammatory mechanisms in LPS-stimu-
lated RAW264.7 macrophages model. Aciculatin was
found to decrease LPS-induced iNOS and COX-2
expression, and this effect was correlated with its inhibi-
tory effect on NF-B activation. These findings together
suggest that aciculatin is a potential therapeutically anti-
inflammatory agent.
Materials and methods
Reagents and materials
Aciculatin was extracted and purified by one of our col-
leagues (Dr. Chien-Chih Chen) to a purity of greater
than 98% by HPLC and NMR. Its structure is shown in
Figure 1. Mouse monoclonal antibodies against iNOS or
GAPDH were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Rabbit monoclonal antibodies
against COX-2, IKKa, and IBa were purchased from
Epitomics Inc. (Burlingame, CA, USA). Rabbit polyclo-
nal antibodies against phosphor-IKKa (Ser180)/IKKb
(Ser181), phosphor-ERK1/2 (Thr202/Tyr204), phosphor-
p38 (Thr180/Tyr182), phosphor-MKK4 (Ser257/
Thr261), MKK4, Phosphor-MKK3/MKK6 (Ser189/207),
MKK3, MEK1/2 and rabbit monoclonal antibodies
against phosphor-IBaa (Ser32), phosphor-p65 (Ser536),
phosphor-JNK (Thr183/Tyr185), phosphor-MEK1/2
(Ser217/221) were purchased from Cell Signaling Tech-
nology (Danvers, MA, USA). Mouse monoclonal anti-
NF-B p65 antibody was obtained from BioVision
(Mountain View, CA, USA). Horseradish peroxidase
(HRP)-conjugated goat anti-mouse or anti-rabbit IgG
antibodies were obtained from Jackson ImmunoResearch
Inc. (Cambridgeshire, UK). Prostaglandin E2 immunoas-
say kits were purchased from R&D Systems (Minneapo-
lis, MN, USA). The pGL4.74[hRluc/TK] and pGL4.32
[luc2P/NF-B-RE/Hygro] vectors were obtained from
Promega Corp. (Madison, WI, USA) and the pEGFP-N1
plasmid was provided by C.-M. Teng (National Taiwan
University, Taipei, Taiwan). TurboFect™ in vitro trans-
fection reagent was obtained from Fermentas (Burling-
ton, Ontario, Canada). All other chemicals were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Figure 1 Chemical structure of aciculatin.
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Mouse macrophage cell line RAW264.7 was obtained
from the Bioresource Collection and Research Center.
Cells were cultured in Dulbecco’s modified Eagle’sm e d -
ium (DMEM; Gibco Laboratories Inc.) supplemented
with 10% (v/v) fetal bovines e r u m( F B S ;I n v i t r o g e n ™
Life Technologies, Carlsbad, CA, USA), 100 U/mL of
penicillin, and 100 μg/mL of streptomycin (Biological
Industries, Kibbutz Beit Haemek, Israel) at 37°C in a
humidified atmosphere of 5% CO2 in air. The medium
was replaced every 3 days.
Nitrite and prostaglandin E2 (PGE2) assays
Nitrite production was measured in RAW264.7 macro-
phage supernatants. Briefly, cells (5 × 10
5 cells) were cul-
tured in 24-well plates and stimulated with LPS (1 μg/mL)
for 24 h. Then 100 μL of Griess reagent was mixed with
100 μL of the cell supernatant and the optical density at
550 nm was measured. The concentration of nitrite was
calculated from a standard curve prepared using known
concentrations of sodium nitrite dissolved in DMEM med-
ium. In the prostaglandin E2 assay, RAW264.7 macro-
phages (2 × 10
5) were cultured in 24-well plates and
stimulated with LPS (1 μg/mL) for 24 h, then PGE2 in the
culture supernatant was measured using a commercial kit,
according to the vendor’s instructions.
Cell viability assay
Cell viability was measured by the colorimetric 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) assay. Cells (1 × 10
4) in 100 μL of medium in 96-
well plates were incubated with vehicle or test compound
for 48 h. Then 25 μL of 1 mg/mL MTT was added and the
plate was incubated at 37°C for 2 h. The cells were then
pelleted and lysed in 100 μL of dimethyl sulfoxide and the
absorbance at 550 nm was measured on a microplate
reader.
Immunoblot analysis
Cells were incubated for 10 min at 4ºC in 20 mM HEPES,
pH 7.4, 2 mM EGTA, 50 mM b-glycerophosphate, 0.1%
Triton X-100, 10% glycerol, 1 mM DTT, 1 μg/mL of leu-
peptin, 5 μg/mL of aprotinin, 1 mM phenylmethylsulfonyl
fluoride, and 1 mM sodium orthovanadate, then were
scraped off, incubated on ice for a further 10 min, and cen-
trifuged at 17,000 g for 30 min at 4ºC. The whole cell
extract (60 μg of proteins) was mixed with an equal volume
of reducing SDS sample buffer (62.5 mM Tris-HCl, pH 6.8,
2% SDS, 1% glycerol, 300 mM 2-mercaptoethanol, and
0.00125% bromophenol blue) and the mixture was heated
at 95ºC for 5 min, electrophoresed on 10% SDS gels, and
the proteins were transferred onto polyvinylidene fluoride
membranes. Immunoblotting was performed by incubation
with the relevant primary antibodies, followed by
incubation for 1 h at room temperature with the corre-
sponding HRP-conjugated secondary antibodies, and
detection using ECL reagents (Amersham Biosciences) and
exposure to photographic film.
RT-PCR analysis
Total RNA was isolated from cells using TRIzol reagent
(Invitrogen). Single-strand cDNA for a PCR template was
synthesized from 10 μg of total RNA using random pri-
mers and Moloney murine leukemia virus reverse tran-
scriptase (Promega). The oligonucleotide primers used for
the amplification were: for mouse iNOS (GenBank Acces-
sion No. NM010927), sense (3126-3151), 5’-CCC TTC
CGA AGT TTC TGG CAG CAG C-3’ and antisense
(3598-3623) 5’-GGC TGT CAG AGA GCC TCG TGG
CTT TGG-3’, with a product of 497 bp, and for mouse
COX-2 (GenBank Accession No. NM0111198), sense
(149-167) 5’-CAG CAA ATC CTT GCT GTT-3’ and anti-
sense (646-666) 5’-TGG GCA AAG AAT GCA AAC
ATC-3’, with a product of 517 bp. b-actin was used as the
internal control; the b-actin primers were sense (613-632),
5’-GAC TAC CTC ATG AAG ATC CT-3’ and antisense
(1103-1122), 5’-CCA CAT CTG CTG GAA GGT GG-3’,
with a product of 510 bp. Equal amounts of each reverse-
transcription product (1 μg) were PCR-amplified using
Taq polymerase in 35 cycles of 1 min at 95°C, 1 min at
58°C, and 1 min at 72°C. The amplified cDNA was run on
1% agarose gels and visualized under UV light following
staining with SYBR Safe DNA gel stain (Invitrogen).
Construction of iNOS and COX-2 promoter-luciferase
plasmids
The mouse iNOS promoter region from -1588 to +165 bp
was amplified from mouse genomic DNA by PCR using
the primers 5’-CTCGAGGACTTTGATATGCT-
GAAATCCATA-3’ (sense) and 5’-AAGCTTAGTTGAC-
TAGGCTACTCCGTG-3’ (antisense) and ligated into the
pGL3-basic vector (Promega, Madison, WI, USA). The
mouse COX-2 promoter region from -996 to +70 bp rela-
tive to the transcription start was amplified from mouse
genomic DNA using the primers 5’-CTCGAGTGGC-
CAACACAAACACAGTAG-3’ (sense) and 5’-AAGCTT
CAGTGCTGAGATTCTTCGTGA-3’ (antisense). Each 5’
amplimer contained a XhoI site and each 3’ amplimer a
HindIII site, such that the XhoI/HindIII-treated resulting
PCR product could be ligated in-frame into the unique
XhoI/HindIII site in the pGL3-basic plasmid (Promega).
Sequence identities were confirmed using an ABI PRISM
377 DNA Analysis System (Perkin-Elmer Corp., Taipei,
Taiwan).
Transient transfection and reporter gene assay
Cells (1 × 10
6) in 1 mL of DMEM medium were seeded
in each well of 6-well plates one day before transfection.
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1 μL of TurboFect™ (Fermentas) and 1 μg of plasmid
DNA, pEGFP-N1 plasmid, or pGL4.74[hRluc/TK] vector
in 100 μL of DMEM serum-free medium was incubated
for 20 min at room temperature, then added to the
cells, which were then incubated for 24 h. Transfection
efficiency, determined by fluorescence microscopy, was
> 60% in all experiments. For the reporter gene assay,
100 μL of reporter lysis buffer (Promega) was added to
each well and the cells were scraped off from the dishes.
The samples were centrifuged at 16,200 g for 30 s at
4ºC, and the supernatants were collected. Aliquots of
cell lysates (20 μL) containing equal amounts of protein
(80 μg) were placed in the wells of an opaque black 96-
well microtiter plate and 40 μLo fl u c i f e r a s es u b s t r a t e
(Promega) was added and the luminescence was imme-
diately measured in a microplate luminometer (Packard,
Meriden, CT, USA). To take into account for possible
differences in transfection efficiency, the luciferase activ-
ity value was normalized using the luminescence from
the cotransfected renilla pGL4.74[hRluc/TK] vector
(Promega).
Confocal microscope analysis
Cells were pretreated with aciculatin for 1 h before stimu-
lation with 1 μg/mL LPS for another 1 h. The cells were
incubated for 1 h then fixed with 4% paraformaldehyde in
PBS for 20 min and permeabilized with 0.5% Trixon
X-100 for 15 min. After 1 h incubation with blocking buf-
fer (5% BSA in PBS), cells were incubated with primary
antibodies (1:100) in 0.5% BSA for 60 min at room tem-
perature. After 3 × 10 min washes in PBS, the cells were
stained for another 60 min with FITC-conjugated second-
ary antibodies (1:100 dilution in PBS), then were viewed
and photographed under a Leica TCS SP5 confocal laser-
scanning microscope using appropriate fluorescence
filters.
Data analysis
The data are expressed as the mean ± S.E.M. and were
analyzed using one-way ANOVA. When ANOVA showed
significant differences between groups, Tukey’sp o s th o c
test was used to determine the specific pairs of groups
showing statistically significant differences. A p value of
less than 0.05 was considered statistically significant.
Results
Effects of Aciculatin on the LPS-Induced NO and PGE2
Production
To investigate whether aciculatin has anti-inflammatory
activities, LPS-induced NO and PGE2 production was
determined in the presence or absence of aciculatin
(1-10 μM) in RAW264.7 mouse macrophage cells.
Measurement of nitrite as an index of NO production
w a sd o n eb yt h eG r i e s sm e t h od. A significant level of
nitrite was detected (43.24 ( 0.37 μM) at 24 h after LPS
treatment in RAW264.7 macrophages (Figure 2A). The
peak level of nitrite concentration (86.72 (0.25 μM) was
reached after 36 h and remained this level till at least
48 h (85.64 ( 0.82 μM) after LPS treatment. Aciculatin
significantly attenuated LPS-induced nitrite production
in a concentration-dependent manner (1-10 μM) from
24 to 48 h. Similar inhibitory effect of aciculatin was
also found in LPS-induced PGE2 production (Figure
2B). Aciculatin concentration-dependently inhibited
LPS-mediated PGE2 production from 12 to 36 h. This
inhibition was not due to cytotoxicity, since none of the
treatments had any significant effect on cell viability at
48 h, as assessed using the MTT assay (Figure 2C).
Aciculatin Inhibits LPS-Induced iNOS and COX-2 Gene and
Protein Expression
We next to determine whether the inhibitory effect of
aciculatin in NO and PGE2 production was due to a
decrease in expression of iNOS and COX-2. The steady-
state levels of iNOS/COX-2 mRNA and proteins follow-
ing drug treatment were measured by using RT-PCR
and immunoblot assays. LPS treatment was shown to
induce extensive iNOS and COX-2 mRNA (Figure 3A)
and proteins expression (Figure 3B), respectively. Acicu-
latin markedly decreased LPS-induced iNOS and COX-2
mRNA and protein levels in a concentration-dependent
manner in RAW264.7 macrophage cells. To further
study the effect of aciculatin on iNOS, COX-2 gene
expression, cells were transiently transfected with repor-
ter plasmids containing the promoters for mouse iNOS
and COX-2. Treating RAW264.7 macrophages with LPS
(1 μg/mL) for 24 h led to an approximately 7.2- or 3.8-
fold increase in iNOS (Figure 3C) and COX-2 (Figure
3D) promoter activity, respectively. These effects were
significantly inhibited by aciculatin (10 μM) as the levels
of iNOS and COX-2 promoter activities returned to
basal level. Collectively, these results demonstrate that
aciculatin suppressed the expression of iNOS and COX-
2 in LPS-stimulated macrophages.
Aciculatin Suppresses IKK/IB/NF-B Signals and NF-B
Nuclear Translocation in LPS-Activated Macrophages
It has been reported that NF-B signals regulate the
transcription of a wide array of genes, including pro-
inflammatory enzymes iNOS and COX-2 in macrophages
[18,19]. However, the precise role of aciculatin on regulat-
ing NF-B activation is still unclear. To examine whether
aciculatin regulates NF-Bp a t h w a y s ,R A W 2 6 4 . 7m a c r o -
phages were treated with LPS (1 μg/mL) for 24 h in the
presence or absent of aciculatin (3, 10 μM) and levels of
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p65 were also examined. LPS treatment not only mediated
significant phosphorylation of IKK(/( at serine 180/181,
the phosphorylation of IBa at serine 32, and IBaa
degradation, but also increased the phosphorylation of p65
(Figure 4A). However, 3 μM aciculatin treatment remark-
ably prevented IKK/IB/p65 phosphorylation and IB
degradation; 10 μM aciculatin even more significantly res-
cued to reach basal level. The result of promoter activity
assay also showed that aciculatin markedly inhibited
LPS-mediated NF-B promoter activation in a concentra-
tion-dependent manner (Figure 4B). Furthermore, the
nuclear translocation of NF-B/p65 was observed under a
laser confocal microscope. RAW264.7 macrophages sti-
m u l a t e dw i t hL P Ss h o w e dad r a m a t i ci n c r e a s ei nt h e
translocation of NF-B into the nucleus (Figure 5). In con-
trast, the LPS-induced NF-B nuclear translocation was
markedly impaired after aciculatin (10 μM) treatment.
These results demonstrate that aciculatin significantly
inhibited IKK/IB/NF- Bp a t h w a y sa n dN F - B nuclear
translocation.
Aciculatin Inhibits Phosphorylation of JNK and p38 MAPK
in LPS-Stimulated Macrophages
MAPKs pathways are also involved in the regulation of
proinflammatory mediator expression [21]. Treatment
with LPS for 30 min resulted in a significant increase in
the phosphorylation of JNK, p38, and ERK compared to
the control group (Figure 6A). Aciculatin (1-10 μM) mark-
edly prevented LPS-induced increase of JNK and p38
phosphorylation in a concentration-dependent manner,
but not phosphorylation of ERK (Figure 6B). Furthermore,
activation of MAPKs (JNK, p38, and ERK) is known to
require both tyrosine and threonine phosphorylation by
the activated MAPKKs (MKK4, MKK3/6, and MEK1/2),
therefore we next to investigate whether aciculatin has
inhibitory effect on the activation of MAPKKs. As shown
in Figure 6C, LPS treatment mediated a significant
increase in the phosphorylation of MKK4, MKK3/6, and
MEK1/2. Interestingly, consistent with the inhibitory effect
on MAPKs, aciculatin concentration-dependently inhib-
ited LPS-mediated increase of MKK4 and MKK3/6 phos-
phorylation, but not phosphorylation of MEK1/2.
Figure 2 The concentration-dependently suppressive effects of aciculatin on the LPS-induced production of nitric oxide (NO) and
PGE2. RAW264.7 cells (2 × 10
5) in 24-well plates were incubated with aciculatin (1-10 μM) for 30 min, followed by stimulation with LPS (1 μg/
mL) for different periods of time in the continued presence of aciculatin. Then the supernatants were collected and assayed for (A) nitrite and
(B) PGE2. C. Viability of RAW264.7 cells was determined with treatment of 1-10 μM aciculatin for 48 h in comparison with the control group
using the MTT assay. The data are the mean ± S.E.M. for four replicates. * p < 0.05 and ** p < 0.01 compared to the indicated groups. The
experiment was performed four times with similar results.
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macrophages. A. 1×1 0
6 RAW264.7 cells were treated with aciculatin (1-10 μM) for 30 min, then stimulated with LPS (1 μg/mL) for 5 h, mRNA
of iNOS and COX-2 were measured by RT-PCR. B. Treatment of RAW264.7 macrophages with aciculatin (1-10 μM) for 30 min followed by
stimulation with LPS (1 μg/mL) for 24 h in the continued presence of aciculatin. Then the cells were harvested and whole cell extracts were
prepared for Western blot analysis for the indicated proteins. C. Cells (1 × 10
5 cells) were transiently transfected with 1 μg of plasmid pGL3-
miNOS or pGL3-mCOX-2 for 24 h, then were treated with 10 μM aciculatin for 30 min, followed by stimulation with LPS (1 μg/mL) in the
continued presence of the aciculatin for another 24 h. Luciferase activity was then measured as described in the Materials and Methods. The
results are expressed as the mean ± S.E.M. for three separate experiments, each with three replicates. * p < 0.05 and ** p < 0.01 compared with
the control group; ## p < 0.01 for comparison of indicated groups.
Hsieh et al. Journal of Biomedical Science 2011, 18:28
http://www.jbiomedsci.com/content/18/1/28
Page 6 of 11Figure 4 Aciculatin suppresses NF-B activation in LPS-activated macrophages. A. RAW264.7 macrophages (1 × 10
6 cells) were treated
with aciculatin (3, 10 μM) for 30 min and stimulated with LPS (1 μg/mL) for 24 h. Then the cells were harvested and whole cell extracts were
prepared for Western blot analysis for the indicated proteins. B. Cells (1 × 10
5 cells) were transiently transfected with 1 μg of pGL4.32[luc2P/NF-
B-RE/Hygro] for 24 h and treated with 1-10 μM aciculatin for 30 min before stimulation with LPS (1 μg/mL) for a further 24 h. Luciferase activity
was measured as described in the Materials and Methods. The results are expressed as the mean ± S.E.M. for three separate experiments, each
with three replicates. ** p < 0.01 compared to the control group; # p < 0.05 and ## p < 0.01 for comparison of indicated groups.
Figure 5 Effect of aciculatin on LPS-induced NF-B translocation into the nucleus. RAW264.7 cells (1 × 10
5 cells) were pretreated with
aciculatin (10 μM) for 1 h followed by stimulation with LPS (1 μg/mL) for 1 h. Samples were stained by anti-p65 antibody (BioVision) and DAPI,
then prepared for confocal microscopy analysis. The results shown are representative of those obtained in four independent experiments. Scale
bar = 10 μm.
Hsieh et al. Journal of Biomedical Science 2011, 18:28
http://www.jbiomedsci.com/content/18/1/28
Page 7 of 11Together, these results indicate that aciculatin act as a
potent anti-inflammatory agent by inhibiting LPS-
mediated iNOS and COX-2 synthesis via suppressing
NF-B and JNK/p38 MAPK activation pathways.
Discussion
In this study, we demonstrated that anti-inflammatory
activities of aciculatin, a main component that isolated
from Chrysopogon aciculatis, in LPS-stimulated
RAW264.7 macrophages. Potently dual inhibitory activ-
ities against iNOS and COX-2 in vitro were shown, sug-
gesting its potential therapeutic usage as a novel topical
anti-inflammatory agent.
It has known that LPS elicits strong immune responses,
including the production of NO, PGE2, and cytokines
(e.g. TNF-a, IL-1b, and IL-6) in macrophages [24,25].
Excess amounts of NO and PGE2 play a critical role in
the aggravation of circulatory shock and chronic inflam-
matory diseases, such as septic shock [26,27], inflamma-
tory hepatic dysfunction [27], inflammatory pulmonary
disease [28], and colitis [29]. Recently, mounting evidence
both in vitro [13,14] and in vivo [30] have indicated an
existing cross talk between the release of NO and PGs in
the modulation of molecular mechanisms that regulate
PGs generating pathway. A group at Monsanto [31]
observed that while the production of both nitrite and
PGE2 was blocked by the NOS inhibitors in mouse
macrophages RAW264.7 cells, these inhibitory effects
were reversed by co-incubation with the precursor of NO
synthesis, L-Arginine. Furthermore, it was also observed
that exogenous NO increased COX-2 activity in the IL-
1b-stimulated fibroblasts by at least 4-fold, suggested NO
Figure 6 Aciculatin suppresses JNK, p38 MAPKs and MKK4, MKK3/6 phosphorylation in LPS-activated macrophages. RAW264.7 cells (1 ×
10
6) were treated with (A) 1 μg/mL LPS for the indicated time periods or (B, C) 1 μg/mL LPS with or without aciculatin (1-10 μM) for 30 min,
and cell lysates were then subjected to western blot analysis for the indicated proteins.
Hsieh et al. Journal of Biomedical Science 2011, 18:28
http://www.jbiomedsci.com/content/18/1/28
Page 8 of 11directly interacts with COX-2 to cause enzymatic activity.
Recent studies indicated that NO S-nitrosylates COX-2
in macrophages [9] and cytosolic phospholipase A2a
(cPLA2a) in human epithelial cells [32] and thus activates
COX-2 and cPLA2a, which provide mechanistic explana-
tion for NO-induced COX-2 activation. In addition, inhi-
bition of iNOS activity by nonselective NOS inhibitors
attenuated the release of NO and PG simultaneously in
LPS-activated macrophages [33,34], suggested that endo-
genously released NO from macrophages exerted a sti-
mulatory action on enhancing the PGs production.
Conversely, it has been shown that COX activation in
turn modulates L-arginine-NO pathway, whereas COX
inhibition decreases NOS activity in human platelets
[35]. These results are indicative of the cross-talk
between NO and PGs pathways. Furthermore, LPS-trea-
ted rat gastric mucosa also demonstrated PGE2 enhances
the release of NO after activation of iNOS [36]; suggest
the cross-regulation of PGE2 and iNOS existed in LPS-
treated condition. Thus, the anti-inflammatory agents
that decrease NO and PGs production by simultaneously
i n h i b i t i n gt h ei N O Sa n dC O X - 2g e n em a yh a v eap o t e n -
tially therapeutic effect in the treatment of inflammatory
and infectious diseases. According to our results, acicula-
tin inhibited LPS-induced NO and PGE2 production in a
concentration-dependent manner by decreasing the
expression of iNOS and COX-2 at both gene and protein
level in mouse macrophages. These results suggested that
aciculatin might inhibit NO and PGE2 production by reg-
ulating the transcription molecules of iNOS and COX-2,
which could be activated by LPS treatment. In addition,
although previous study suggests that aciculatin may
have DNA binding activity [37], we noted that reported
concentration of aciculatin was higher than we used; sug-
gest that DNA binding effect may not be the major con-
cern in this study. Furthermore, our result of chromatin
precipitation assay (supplemental figure 3) clearly
demonstrated that aciculatin directly inhibited LPS-
induced NF-B binding to the promoter of COX-2 and
iNOS.
Many studies have demonstrated that LPS induces
IKK/IB/NF-B pathway to stimulate the production of
inflammatory cytokines, chemokines, and proinflamma-
tory enzymes (e.g. iNOS and COX-2) [38-40]. The pro-
moter of the iNOS and COX-2 genes are known to
contain two transcriptional regions, an enhancer and a
basal promoter [41]. There are several binding sites for
transcription factors, including NF-B, which are
located in both the enhancer and basal promoter [42].
NF-B binding site has been identified on the murine
iNOS and COX-2 promoters as well and has been
observed to play a role in the LPS-mediated induction
of iNOS and COX-2 in macrophages [43]. Under unsti-
mulated condition, NF-B is located in the cytosol and
is bound to the inhibitory IB protein. The activation of
NF-B in response to LPS stimulation leads to increase
of nuclear translocation and DNA binding ability,
followed by phosphorylation, ubiquitination, and proteo-
some-mediated degradation of IB proteins [38-40]. Our
results demonstrated that aciculatin has the ability to
inhibit the LPS-induced phosphorylation of IKKa/b,
IBa, p65 and IBa protein degradation as well as p65
nuclear translocation. LPS-mediated iNOS, COX2, and
NF-B promoter activations were also markedly inhib-
ited by aciculatin as shown in the promoter activity
assay. These results clearly demonstrated that aciculatin
suppresses LPS-induced NF-B-dependent signals to
regulate iNOS and COX-2 expression.
In addition to NF-B, LPS is a potent activator of
MAPK pathways [44]. MAPKs not only play an impor-
tant role in the LPS-mediated expression of iNOS and
COX-2 in mouse macrophages [38-40,44], but also regu-
late cytokine release [21]. However, using specific inhibi-
tors, different groups [45,46] demonstrated that
treatment of MEK1/2 inhibitor, PD98059, was not
observed significantly inhibitory effect on NO produc-
tion and iNOS protein expression in LPS-activated
macrophages, suggesting activation of ERK may not the
major modulate pathway in LPS-induced NO produc-
tion [45]. In this study, aciculatin treatment markedly
suppressed LPS-stimulated phosphorylation of MAPKKs
(MKK4 and MKK3/6) and MAPKs (JNK and p38), these
results suggest that suppression of JNK/p38 MAPK
phosphorylation by aciculatin might also be involved in
inhibition of the LPS-induced production of pro-inflam-
matory substances in RAW 264.7 cells.
In conclusion, our observations support the evidence
that aciculatin exerts anti-inflammatory effect by inhibit-
ing the expression of LPS-stimulated iNOS and COX-2
inflammation-associated genes via suppression of tran-
scription factor NF-B activation and JNK/p38 MAPKs
pathway. In view of the fact that NO and PGE2 play
important roles in mediating inflammatory responses, it
suggests that aciculatin might be a potential anti-inflam-
matory agent.
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